However, at 14 days after mMSC administration, the SP-A protein expression level in the LPS+mBM-MSC-p130 and LPS+mBM-MSC-E2F4 groups but not in the LPS+mBM-MSC and LPS+mBM-MSC-NC groups increased significantly compared to that in the ARDS group (p < 0.05), while the SP-A protein expression level in the LPS+mBM-MSC-p130 and LPS+mBM-MSC-E2F4 groups was increased significantly compared to that in the LPS+mBM-MSC-NC group (p < 0.05). This evidence concerns the gene E2F4 and acute respiratory distress syndrome.